🔗 Share this article

Given that the US continues making historic adjustments to its vaccination schedules, an unexpected name has surfaced somewhat surprisingly: Høeg, a US-based sports physician and public health researcher who initially gained attention by casting doubt on coronavirus vaccines throughout the pandemic and has concentrated on possible fatalities after Covid immunization in her short time at the US Food and Drug Administration (FDA).

Scheduled Changes to Childhood Immunization Schedule

Public health authorities were set to unveil radical revisions to the childhood immunization program in December, synchronizing the US with the Danish immunization schedule, according to reports – a significant shift that would put the US at odds with a large portion of the international standard with no evidence for benefit. The announcement has been postponed until the next year.

Instead of the director of the vaccine center, Dr. Høeg is listed to speak at the meeting. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth person to lead the center this year.

A New Direction at the Agency

Høeg's temporary position could signify a tighter collaboration between the drug and biologics divisions as Dr. Høeg and Prasad solidify control at the agency – and it signals a greater focus upon reevaluating long-standing vaccines at the FDA.

Dr. Høeg has frequently advocated for ending specific pediatric immunization guidelines in the US so as to align more in line with the Danish model, a society with nationalized medicine and a population approximately the population of the state of Wisconsin.

To date statements, she has kept her attention on vaccination policy – usually the responsibility of Dr. Prasad, head of the FDA’s vaccine center – rather than pharmaceutical oversight.

Questions Over Background

Dr. Høeg has no apparent background in medication creation, approval processes or leadership, which has been customary for past directors of the CBER. She has served at the FDA as a senior adviser to the commissioner and CBER since earlier this year.

“She doesn’t seem to have the necessary background” for running the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She’s never run a scientific study. She has no expertise in running a large organization. She lacks background in pharmaceutical oversight.”

Previous commissioners of the center would “be deeply familiar with regulatory frameworks and the research of drug development”, commented a former acting FDA commissioner. “Objectively, she has not acquired the kind of background that previous people who ran CBER have had.”

This division has an vast portfolio at the agency, she pointed out.

“The public just zeroes in on the innovative therapies, but the generic drug division clears numerous off-brand pharmaceuticals. There is also a biosimilars division, non-prescription drug unit and other areas, and each of these need to be looked after,” Dr. Woodcock noted. “The responsibility you overlook, that is the part that I always told people is going to cause problems.”

Additionally, a significant leadership aspect to the position, which supervises in excess of 5,000 employees. “It’s a massive administrative position, if you execute it properly,” she concluded.

Agency Reaction and Controversial Initiatives

When asked about inquiries about Dr. Høeg's fitness for the role and whether this appointment indicates greater collaboration among regulatory chiefs on vaccines, a press secretary said that the “questions are based on incorrect premises”.

“Her experience matches the responsibilities of her position,” the spokesperson said, noting the period Høeg spent guiding the agency head on “pharmaceutical safety and oversight research, including computational safety modeling and shot safety tracking”.

As acting director, Høeg assumes responsibility for the commissioner’s new priority voucher program, a contentious rapid drug-approval program that allegedly troubled her preceding directors. “By what process are these drugs being picked for this fast-track system? Who makes the decisions?” Howard questioned. “There’s a lot of secrecy occurring at the FDA right now.”

Overall, he said, “the Food and Drug Administration seems to be moving towards laxer rules of most medications, except for shots.”

Public History on Vaccines

With vaccines, Høeg has a clearer, if concerning, track record, Howard observe. She authored a analysis using unverified crowd-sourced reports to estimate the incidence of myocarditis following COVID-19 immunization. She advised the state of Florida top health official Dr. Joseph Ladapo, who was said to have altered data to indicate Covid vaccinations are riskier than they are.

Part of her “desired changes” for the new federal leadership encompassed revising regulations for recently developed shots and ending “optional” immunizations, she stated post-election on a audio program. At the FDA, Høeg has allegedly proposed barring adolescent males from getting Covid vaccinations.

“She is an thorough ideologue who starts off with her preconceived notions and tailors the evidence to fit the evidence in a highly misleading, untruthful way,” Howard stated.

Consolidating Power and a “Revenge Tour”

Dr. Høeg aligned with other contrarians, {like|